To the Editor: Use of bisphosphonates for fracture prevention is increasing. These agents have potential adverse effects,1 but are not known to cause myocardial injury. We present a case of myopericarditis following administration of intravenous zoledronic acid.
Publication of your online response is subject to the Medical Journal of Australia's editorial discretion. You will be notified by email within five working days should your response be accepted.